SAN DIEGO -- The risk of progression from smoldering multiple myeloma to symptomatic disease decreased by 50% in patients treated with the anti-CD38 monoclonal antibody daratumumab (Darzalex), ...

CAR-T cell therapy provides long, treatment-free remissions for relapsed multiple myeloma, using genetically modified T cells ...

To Jagannath, cure means long periods of disease-free survival as defined by minimal residual disease (MRD) criteria, 10 -5 ...

Findings from a study on the role of exosomal non-coding RNAs (ncRNAs) in the progression of multiple myeloma (MM), with a specific focus on sex-based differences, show that while male and female ...

Multiple myeloma is a relatively uncommon cancer of plasma cells, where excessive proliferation of these malignant cells within the bone marrow leads to abnormal antibody production. The disease ...

Data show that patients’ multiple myeloma still fails to progress if patients receive less-frequent Tecvayli. A reduced dosing schedule of Tecvayli (teclistamab) continued to slow the progression of ...

Discover the latest breakthroughs in multiple myeloma treatment, including CAR T-cell therapies and promising new options for ...

Please provide your email address to receive an email when new articles are posted on . The diet intervention appeared safe and feasible. It also improved quality of life and exhibited favorable ...

A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland. This story was originally published on BioPharma Dive. To receive daily news ...

The U.S. Food and Drug Administration (FDA) approved on Thursday Johnson & Johnson’s (NYSE:JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for a type of blood cancer. Darzalex Faspro is the ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk ...